Get the Stockscreener App
0.5987
5.34%
-0.0338
After Hours:
.60
0.0013
+0.22%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Vaxart Inc stock is traded at $0.5987, with a volume of 244.64K.
It is down -5.34% in the last 24 hours and down -21.21% over the past month.
VAXART INC
See More
Previous Close:
$0.6325
Open:
$0.5981
24h Volume:
244.64K
Relative Volume:
0.66
Market Cap:
$N/A
Revenue:
$237.26M
Net Income/Loss:
$16.33M
P/E Ratio:
10.10
EPS:
0.0593
Net Cash Flow:
$7.57M
1W Performance:
-5.34%
1M Performance:
-21.21%
6M Performance:
+61.81%
1Y Performance:
-35.85%
1-Day Range:
$0.5801
$0.62
1-Week Range:
$0.5801
$0.62
52-Week Range:
$0.33
$0.80
Vaxart Inc Stock (VXRT) Company Profile
Compare VXRT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.5987 | 0 | 237.26M | 16.33M | 7.57M | 0.0593 |
VRTX
Vertex Pharmaceuticals Inc
|
442.96 | 113.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.34 | 66.62B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.41 | 55.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.16 | 40.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
148.49 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-24 | Initiated | Oppenheimer | Outperform |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Nov-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-29-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jun-24-21 | Initiated | Jefferies | Buy |
| Jun-11-21 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
View All
Vaxart Inc Stock (VXRT) Latest News
[DFAN14A] Vaxart, Inc. SEC Filing - Stock Titan
Vaxart Mails a Letter to Shareholders - marketscreener.com
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY - Yahoo Finance
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Vaxart (VXRT) Investors of Securities Fraud Class Action and Encourages Investors with Significant Losses to Contact the Firm, Application Deadline Approaching - TMX Newsfile
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders - The Manila Times
Vaxart Shareholder Alert - TMX Newsfile
Vaxart (NASDAQ: VXRT) Board rebuffs activist slate in contested proxy - Stock Titan
Vaxart director Mark Watson buys $6,530 in company stock By Investing.com - Investing.com South Africa
Vaxart director Mark Watson buys $6,530 in company stock - Investing.com UK
Vaxart, Inc. (VXRT) director adds 10,000 shares in open‑market buy - Stock Titan
Vaxart | 4: Statement of changes in beneficial ownership of securities-Officer Lo Steven - Moomoo
Daniel P. Houle Solicits Proxies from Shareholders of Vaxart - marketscreener.com
Activist group (VXRT) with 1.52M shares seeks majority on Vaxart board via GOLD proxy - Stock Titan
Vaxart (NASDAQ: VXRT) CFO uses 31,395 shares to cover RSU taxes - Stock Titan
Vaxart faces proxy contest ahead of July annual meeting By Investing.com - Investing.com Australia
Vaxart, Inc Provides Information to the Shareholders - marketscreener.com
Vaxart Emphasizes Board Stability and Oral Vaccine Platform Progress Ahead of 2026 Shareholder Vote - Minichart
Vaxart faces proxy contest ahead of July annual meeting - Investing.com UK
Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline - TipRanks
VXRT: Oral pill vaccine platform advances with strong clinical data and extended financial runway - TradingView
Vaxart (NASDAQ: VXRT) proxy fight — Board backs six nominees, urges WHITE card - Stock Titan
Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027 - TradingView
Vaxart (VXRT) readies contested 2026 vote as trial advances and runway extends to 2027 - Stock Titan
Vaxart (VXRT) registers 32.9M shares; up to $25M of issuer financing - Stock Titan
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders - GlobeNewswire
[EFFECT] Vaxart, Inc. SEC Filing - Stock Titan
[S-1/A] Vaxart, Inc. Amends IPO Registration Statement - Stock Titan
Vaxart (VXRT) Institutional Ownership 2026 $VXRT - MarketBeat
Complete Defense Verdict in Rare Securities Class Action Trial - Cornerstone Research
MSN Money - MSN
Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release - MSN
Earnings call transcript: Vaxart’s mixed Q1 2026 results, EPS beats forecast - Investing.com India
Vaxart (VXRT) Reports Progress in Clinical Programs and Financia - GuruFocus
VXRT: Revenue surged and net income turned positive as clinical milestones and funding flexibility advanced - TradingView
Earnings call transcript: Vaxart’s mixed Q1 2026 results, EPS beats forecast By Investing.com - Investing.com South Africa
VXRT: Revenue doubled year-over-year, with clinical milestones and cash runway into Q2 2027 - TradingView
[S-1] Vaxart, Inc. Files IPO Registration Statement - Stock Titan
Vaxart Q1 2026 Earnings Call Transcript - MarketBeat
Vaxart : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
VXRT: Returned to profitability in Q1 2026 with strong revenue growth and improved cash position - TradingView
Vaxart targets Q2 data from 400-person oral COVID vaccine study - Stock Titan
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times
Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Vaxart (OTCQX: VXRT) swings to Q1 2026 profit on BARDA and collaboration revenue - Stock Titan
Vaxart (OTCQX: VXRT) swings to Q1 2026 profit as COVID trial advances - Stock Titan
Vaxart (VXRT) files ATM supplement to raise up to $49.8M via Sales Agents - Stock Titan
Vaxart Inc Stock (VXRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.26%
Cap:
|
Volume (24h):